SSi Canada Partners with SES Networks to Deliver New Satellite Capacity into Northern Canada
Vital new satellite capacity will be delivered to Canada’s north, including all 25 communities of Nunavut, following a partnership signed between SSi Canada, the developer-operator of QINIQ broadband and SSi Mobile services in Nunavut, and SES Networks, the leader in global content connectivity solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210118005410/en/
SSi Canada Partners with SES Networks to Deliver New Satellite Capacity into Northern Canada (Photo: Business Wire)
This partnership comes at a critical time for Nunavut, with the COVID-19 crisis having led to an unprecedented need for reliable internet and mobile communications services as Nunavummiut move increasingly to study, work, and shop online and at home. With growing demand for QINIQ broadband and SSi Mobile services, all 25 communities in Nunavut - and elsewhere in Northern Canada - will benefit from SSi Canada’s multi-year agreement with SES Networks.
“We are excited to partner with SES Networks to bring this much needed capacity to Canada’s North,” said Jeff Philipp, CEO and Founder of SSi. “As a global operator, SES Networks understands the challenges faced by underserved regions of the world and SSi’s ongoing commitment to overcome these challenges. SES Networks is certainly the right partner at the right time.”
Under the new agreement announced today, SSi Canada will secure a significant increase in its satellite capacity, enhancing SSi’s ability to better serve consumers, students, government entities and businesses in Nunavut today and into the future. The new SES-SSi satellite footprint covers much more than Nunavut, enabling connectivity improvements across Canada.
“Thanks to timely regulatory approvals from the Canadian Government, we are now working hard to bring this new capacity online as quickly as possible” said Philipp. “This is an essential step to ensure continuity of QINIQ broadband, and we look forward to expanding our network offerings and capabilities in the coming months and years as we work to deliver on the Government’s goal of broadband connectivity for every Canadian, no matter where they live.”
“For years we’ve been providing services to Northern Canada and know that the digital divide is challenging for people living in remote and rural areas,” said Omar Trujillo, Vice President of Sales, Fixed Data Americas at SES Networks. “Canada’s bold vision to connect every citizen to broadband this decade aligns with the innovative solutions SSi Canada has been providing to its customers for years. We are happy to bring our expertise of operating more than 70 geostationary and medium earth orbit satellites to help SSi Canada scale up their backbone, ensuring that the remote communities in Nunavut are at the forefront in achieving the 50/10 Mbps threshold.”
SES has a proven track record for providing reliable data services across Canada in a variety of spectrum bands over its satellite fleet. Its C-band offerings are uniquely capable for providing the capacity needed for communities and businesses in Canada to maintain and strengthen their communications infrastructure.
Follow SES on:
Social Media
Blog
Media Library
About SSi Canada
Headquartered in Yellowknife, Northwest Territories, with a satellite teleport and network operations centre in Ottawa, SSi designs, builds and operates state-of-the-art communications networks. SSi is a pioneer in delivering remote-area connectivity in Canada’s North and the developer-operator of the award winning SSi Mobile and QINIQ broadband services. With over 30 years of operating experience, SSi is a leader in delivering advanced satellite, broadband, mobile wireless and clean energy solutions. SSi understands first-hand the challenges faced in providing effective and affordable communications services and other infrastructure support to remote and outlying areas, having launched broadband and mobile voice and data services into many markets where these previously did not exist.
For more information, see: http://www.ssicanada.com/
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries almost 8,200 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG).
Further information is available at: www.ses.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210118005410/en/
Contact information
Suzanne Ong
SES External Communications
Tel. +352 710 725 500
suzanne.ong@ses.com
David Veniot
SSi Communications Manager
Tel. 613-271-6464
davidv@ssicanada.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 09:42:00 EET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 09:30:00 EET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 04:06:00 EET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
